News

MNG Laboratories™ Adds Complementary mtDNA Genome Analysis to ID/Autism NGS Panels

Recent studies[1][2] have suggested a connection between mitochondrial DNA (mtDNA) and autism. At MNG Laboratories™, we strive to offer a comprehensive portfolio of tests to provide your patients with the answers they need. Our philosophy of offering mtDNA sequencing and deletion analysis to many of our sequencing panels has resulted in a 15.1% increase in […]


Update on Neurotransmitter Disorders

Dr. Keith Hyland will provide an overview of Serotonin and Catecholamine metabolism, explain how disorders affecting these neurotransmitters are diagnosed within the laboratory and provide an update on the inherited diseases that affect this area of neuro-metabolism. To view webinar recording, click here.


Now Introducing the MNGenome®

MNG is proud to announce the launch of the MNGenome®. This new test sequences the entire human genome, making it our most comprehensive clinical diagnostic test ever. The MNGenome® provides greater sensitivity than whole exome sequencing, since approximately 20% of known pathogenic variants are outside the exon boundaries. The MNGenome® is a comprehensive approach to diagnosis […]


MNG Expands Global Reach with Several New Distributors

MNG Laboratories is pleased to announce the signing of several key international distributor agreements in Asia, Latin America and Eastern Europe. MNG now has active distributors representing our extensive menu of over 500 neurogenetic and biochemical tests in Mexico, Hong Kong, Turkey and Chile. Each distributor was chosen for their clinical expertise, excellent customer service, […]


Introducing the MNG Xpress™ Actionable Epilepsy Panel

MNG is now launching the MNG Xpress™ Actionable Epilepsy panel with a standard STAT turnaround time of < 2 weeks at no additional cost and with no additional requisition forms to fill out. Our Actionable Epilepsy panel is now always STAT. You know MNG as your source for Neurogenetic Answers™ and we pride ourselves on delivering actionable results you can […]


Significant Improvements Made to Our Dystonia Panel Portfolio

We are pleased to announce that we have made substantial improvements in our ability to search for and identify the known pathogenic variants likely to cause dystonia. Our Comprehensive Dystonia Panel now includes 192 genes and 5,048 pathogenic variants associated with conditions linked to dystonia. This panel includes mtDNA sequencing and deletion analysis with the option of adding HTT repeat […]


The Most Comprehensive Exome Available

Now Covering 100% of Expert Approved Pathogenic Variants We are proud to announce that our MNG Exome™ now covers all pathogenic variants that are practice guideline and expert panel reviewed in ClinVar. These include variants located in intronic regions that are not covered by standard exome sequencing. In addition to sequencing, we include copy number analysis, mitochondrial genome […]


Webinar: Use of RNA Sequencing to Improve Diagnostic Sensitivity: What You Need to Know

Next-generation sequencing has evolved into a powerful tool helping thousands get molecular diagnosis of their conditions. In some cases, proving that a specific variant is the cause of a condition can be challenging or impossible based on information available in the literature. This is especially true for variants near intron-exon junctions. Similarly the splicing consequences […]


Expanded SCA Repeat Expansion Testing Now Available

Approximately 50-80% of ataxia cases are caused by repeat expansions, which are not detected by standard sequencing analysis. We recently launched the addition of the 5 most common SCA repeat expansions into our Ataxia/Episodic Ataxia Panels to meet this need. To further support our comprehensive ataxia options and provide the most sensitive testing possible, MNG Laboratories has […]


ASHG 2017 Summary

Featured Presentation MNG Laboratories’ Chief Medical Officer, Dr. Peter L. Nagy, MD, PhD, gave an insightful presentation on exome use in carrier testing. In a review of our data, we found that over 40% of children born with catastrophic or severe disabilities that we diagnosed with rare autosomal recessive conditions carry pathogenic variants that would […]